Abstract |
The prognosis of patients with chronic myeloid leukemia in blastic crisis (CML-BC) remains extremely poor, and multiagent chemotherapy regimens commonly used to treat acute leukemia offer only short-term benefits. Therefore, the advent of the novel molecularly targeted anticancer agent imatinib mesylate is a breakthrough in CML therapy. We present a CML patient in megakaryoblastic crisis with severe myelofibrosis, who was treated with imatinib at a dosage of 400 mg/day and achieved complete remission together with a marked regression of myelofibrosis after 1 month. The effect of imatinib on the long-term prognosis remains unclear, although the agent is clearly a promising drug for treating CML-BC even in cases of myelofibrosis.
|
Authors | Yuka Hirose, Hitoshi Kiyoi, Masanori Iwai, Toshiya Yokozawa, Masafumi Ito, Tomoki Naoe |
Journal | International journal of hematology
(Int J Hematol)
Vol. 76
Issue 4
Pg. 349-53
(Nov 2002)
ISSN: 0925-5710 [Print] Japan |
PMID | 12463599
(Publication Type: Case Reports, Journal Article)
|
Chemical References |
- Antineoplastic Agents
- Benzamides
- Piperazines
- Pyrimidines
- Imatinib Mesylate
|
Topics |
- Adult
- Antineoplastic Agents
(administration & dosage)
- Benzamides
- Blast Crisis
(drug therapy)
- Bone Marrow
(pathology)
- Female
- Humans
- Imatinib Mesylate
- Leukemia, Myelogenous, Chronic, BCR-ABL Positive
(drug therapy, pathology)
- Megakaryocytes
(pathology)
- Piperazines
(administration & dosage)
- Primary Myelofibrosis
(drug therapy, etiology, pathology)
- Pyrimidines
(administration & dosage)
|